LOGO
LOGO

Immunovant Bets Big On IMVT-1402

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Graves' disease is the leading cause of an overactive thyroid, known as hyperthyroidism. This condition occurs when the immune system mistakenly attacks the thyroid gland, causing it to produce excessive amounts of thyroid hormones. The disorder bears the name of Robert James Graves, an Irish doctor who first described it in the 1830s. Beta-blockers, Anti-thyroid medications, Radioactive iodine treatments, and Surgery are some of the treatment options for Graves' disease.

The company we are profiling today is Immunovant Inc. (IMVT), which is developing a drug for Graves' disease.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.